Obstetrics and GynecologyObstetrics and GynecologyАкушерство и гинекология0300-90922412-5679Bionika Media24769310.18565/aig.2016.7.17-21ArticlesСтатьиResearch ArticleCervical cancer screening: What is new in global practice?Скрининг рака шейки матки: что нового в мировой практике?BairamovaGyuldana R.БайрамоваГюльдана Рауфовна

MD, Head of Clinical Research and the outpatient department

д.м.н., зав. по клинической работе научно-поликлинического отделения

bayramova@mail.ruFaizullinLeonid Z.ФайзуллинЛеонид Закиевич

Ph.D., a leading researcher of the laboratory of molecular genetic methods

к.б.н., в.н.с. лаборатории молекулярно-генетических методов

l_faizullin@oparina4.ruKorolkovaAnna I.КорольковаАнна Игоревна

II year intern

ординатор II года обучения

zaikinaai@icloud.comPoloznikovAndrei A.ПолозниковАндрей Александрович

PhD, Head of the Laboratory of Biochemistry and Enzymology

к.х.н., зав. лабораторией биохимии и энзимологии

andrey.poloznikov@gmail.comKiselevVsevolod I.КиселевВсеволод Иванович

Doctor of Biological Sciences, professor, corresponding member of Russian Academy of Sciences, deputy director of the Institute of Biomedical Problems

д.б.н., профессор, член-корр. РАН, зам. директора Института медико-биологических проблем

vkis10@mail.ruResearch Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of RussiaФГБУ НЦАГиП им. академика В.И. Кулакова Минздрава РоссииDmitry Rogachev Federal Research Center of Pediatric Hematology, Oncology and ImmunologyФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава РоссииPeoples’ Friendship University of RussiaФГБУ ВПО РУДН150720167NO7 (2016)№7 (2016)172118022023Copyright ©; 2016, Bionika MediaCopyright ©; 2016, ООО «Бионика Медиа»2016Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/0300-9092/article/view/247693

Objective. To carry out a systematic review of the data available in the modern literature on the role of different molecular genetic markers for cervical carcinogenesis along with traditional cervical cancer screening methods. Material and methods. The review included the data of foreign and Russian articles published over the past 5 years and found in the Pubmed on this topic. Results. The paper describes main methods used for cervical cancer screening, as well as new epigenetic biomarkers that enable proper management tactics to be chosen in difficult clinical situations. Conclusion. Diagnostic biomarkers (WIFI gene methylation, the expression of mir-29b in the cervical epithelium, p16 and Ki67, etc.) play a pivotal role in interpreting the final diagnosis if there are controversial and ambiguous results of cytological examination and HPV testing, which emphasizes the need for their further investigation.

Цель исследования. Провести систематический анализ данных, имеющихся в современной литературе, о роли различных молекулярно-генетических маркеров канцерогенеза шейки матки наряду с традиционными методами скрининга рака шейки матки. Материал и методы. В обзор включены данные зарубежных и отечественных статей, найденных в Pubmed по данной теме, опубликованных за последние 5 лет. Результаты. Описаны основные методы, используемые для скрининга рака шейки матки, а также новые эпигенетические биомаркеры, позволяющие выбрать правильную тактику ведения пациенток в сложных клинических ситуациях. Заключение. Диагностические биомаркеры (метилирование гена WIF1, экспрессия mir-29b в эпителии шейки матки, р16 и Ki67 и др.) играют определяющую роль в интерпретации окончательного диагноза при спорных и неоднозначных результатах цитологического исследования и ВПЧ-тестирования, что подчеркивает необходимость их дальнейшего исследования.

mir-29bhuman papilloma virus (HPV)cervical cancercervical intraepithelial neoplasialiquid-based cytologyHPV testingmicroribonucleic acidmir-29bgene methylationgene expressionвирус папилломы человекарак шейки маткицервикальная интраэпителиальная неоплазияжидкостная цитологияВПЧ-тестированиер16(INK4A)/Ki67 иммуноокрашиваниемикрорибонуклеиновая кислотаметилирование генаэкспрессия генар16/Ki67 immunostainingHPV Information Centre. Human papillomavirus and related diseases in the world. SummaryReport 2015-04-08.Стерн П.Л., Китченер Г.С., ред. Вакцины для профилактики рака шейки матки. Пер. с англ. Сухих Г.Т., Прилепская В.Н., ред. М.: МЕДпресс-информ; 2011. 192с. [Stern P.L., Kitchener G.S., ed. Vaccines for the prevention of cervical cancer. Trans. from English Sukhikh G.T., Prilepskaya V.N., ed. Moscow: MEDpress-inform; 2011. 192p. (in Russian)]Veijalainen O., Tuomisaari S., Luukkaala T., Mäenpää J. High risk HPV testing in the triage of repeat ASC-US and LSIL. Acta Obstet. Gynecol. Scand. 2015; 94(9): 931-6.Шанин А.А., Решетников О.В. Папилломавирусная инфекция, современный подход: эпидемиология, профилактика и лечение. 2013; 15(5): 16-20. [Shanin A.A., Reshetnikov O.V. HPV infection, a modern approach: epidemiology, prevention and treatment. Ginekologiya. 2013; 15(5): 16-20. (in Russian)]Shipitsyna E., Zolotoverkhaya E., Kuevda D., Nasonova V., Romanyuk T., Khachaturyan A. et al. Prevalence of high-risk human papillomavirus types and cervical squamous intraepithelial lesion in women over 30 years of age in St. Peterburg, Russia. Cancer Epidemiol. 2011; 35(2): 160-4.Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Основные показатели состояния онкологической помощи населению Российской Федерации в 2013 г. М.: ФГБУ «МНИОИ им. П. А. Герцена» Минздрава России; 2014. 235с. [Kaprin A.D., Starinskiy V.V., Petrova G.V., eds. The main indicators of the state of cancer care to the population of the Russian Federation in 2013. Moscow: P.A. Hertzen Moscow Oncology Research Institute, Ministry of Health of Russia; 2014. 235p. (in Russian)]Ronco G., Dillner J., Elfström K.M., Tunesi S., Snijders P.J., Arbyn M. et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomized controlled trials. Lancet. 2014; 383(9916): 524-32.Ryu K.J., Lee S., Min K.J., Kim J.W., Hong J.H., Song J.Y. et al. Reflex human papillomavirus test results as an option for the management of Korean women with atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion. Oncologist. 2015; 20(6): 635-9.Stoler M.H., Wright T.C. Jr., Sharma A., Apple R., Gutekunst K., Wright T.L.; ATHENA (Addressing THE Need for Advanced HPV Diagnostics) HPV Study Group. High-risk human papillomavirus testing in women with ASC-US cytology. Results from the ATHENA HPV study. Am. J. Clin. Pathol. 2011; 135(3): 468-75.Saville A.M. Cervical cancer prevention in Australia: Planning for the future. Cancer Cytopathol. 2016; 124(4): 235-40.Stoler M.H., Austin R.M., Zhao C. Point-counterpoint: cervical cancer screening should be done by primary human papillomavirus testing with genotyping and reflex cytology for women over the age of 25 years. J. Clin. Microbiol. 2015; 53(9): 2798-804.Wright T.C., Stoler M.H., Behrens C.M., Sharma A., Zhang G., Wright T.L. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol. Oncol. 2015; 136(2): 189-97.Schiffman M., Boyle S., Raine-Bennett T., Katki H.A., Gage J.C., Wentzensen N. et al. The role of human papillomavirus genotyping in cervical cancer screening: a large-scale evaluation of the cobas HPV test. Cancer Epidemiol. Biomarkers Prev. 2015; 24(9): 1304-10.Wentzensen N., Eetterman B., Castle P.E., Schiffman M., Wood S.N., Stiemerling E. et al. p16/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women. J. Natl. Cancer Inst. 2015; 107(12): djv257.Apgar B.S., Brotzman G.L., Spitzer M. Colposcopy: principles and practice. 2nd ed. Saunders; 2008. 560p.Blatt A.J., Kennedy R., Luff R.D., Austin R.M., Rabin D.S. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015; 123(5): 282-8Bergeron C., Ordi J., Schmidt D., Trunk M.J., Keller T., Ridder R.; European CINtec Histology Study Group. Conjunctive p16 (INK4a) testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am. J. Clin. Pathol. 2010; 133(3): 395-406.del Pino M., Garcia S., Fuste V., Alonso I., Fuste P., Torne A., Ordi J. Value of p16 (INK4a) as a marker of progression/regression in cervical intraepithelial neoplasia grade 1. Am. J. Obstet. Gynecol. 2009; 201(5): 488. el-7.Klaes R., Friedrich T., Spitkovsky D., Ridder R., Rudy W., Petry U. et al. Overexpression of p16 (INK4a) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int. J. Cancer. 2001; 92(2): 276-84.Прилепская В.Н., Байрамова Г.Р., Коган Е.А., Чернова В.Ф., Окушко А.Н. Новые возможности ранней диагностики и профилактики ВПЧ-ассоциированных поражений шейки матки. Медицинский совет. 2015; XX: 72-7. [Prilepskaya V.N., Bayramova G.R., Kogan E.A., Chernova V.F., Okushko A.N. New features of HPV-associated cervical lesions early diagnosis and prevention. Meditsinskiy sovet. 2015; XX: 72-7. (in Russian)]Castle P.E., Dockter J., Giachetti C., Garcia F.A., McCormick M.K., Mitchell A.L. et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin. Cancer Res. 2007; 13(9): 2599-605.Sotlar K., Stubner A., Diemer D., Menton S., Menton M., Dietz K. et al. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J. Med. Virol. 2004; 74(1): 107-16.Karlsen F., Keegan H., McInerney J., Pilkington L., Gronn P., Silva I. et al. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens. J. Virol. Methods. 2009; 155(1): 61-6.Белоцерковцева Л.Д., Коваленко Л.В., Лескова С.В. Роль экспрессии онкобелка Е7 в ранней диагностике шейки матки. Медицина и образование в Сибири. 2013; 4: 75. [Belotserkovtseva L.D., Kovalenko L.V., Leskova S.V. The role of the E7 oncoprotein expression in the early diagnosis of cervical. Meditsina i obrazovanie v Sibiri. 2013; 4: 75. (in Russian)]Ikenberg H., Bergeron C., Schmidt D., Griesser H. Screening for cervical cancer precursors with p16/ Ki-67 dual-stained cytology: results of the PALMS study. J. Natl. Cancer Inst. 2013; 105(20): 1550-7.Файзуллин Л.З., Карнаухов В.Н., Мзарелуа Г.М., Чернова В.Ф. Экспрессия микроРНК при цервикальной интраэпителиальной неоплазии и раке шейки матки. Акушерство и гинекология. 2015; 9: 27-32. [Faizullin L.Z., Karnaukhov V.N., Mzarelua G.M., Chernova V.F. MicroRNA expression in cervical intraepithelial neoplasia and cancer of the cervix uteri. Akusherstvo i ginekologiya/Obstetrics and Gynecology. 2015; (9): 27-32. (in Russian)]Filipowicz W., Bhattacharyya S.N., Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 2008; 9(2): 102-14.Xu L., Qi X., Duan S., Xie Y., Ren X., Chen G. et al. MicroRNAs: potential biomarkers for disease diagnosis. Biomed. Mater. Eng. 2014; 24(6): 3917-25.Hayes J., Peruzzi P.P., Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol. Med. 2014; 20(8): 460-9.Ai L., Tao Q., Zhong S., Fields C.R., Kim W.J., Lee M.W. et al. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis. 2006; 27(7): 1341-8.Yee D.S., Tang Y., Li X., Liu Z., Guo Y., Ghaffar S. et al. The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol. Cancer. 2010; 9: 162.Delmas A.L., Riggs B.M., Pardo C.E., Dyer L.M., Darst R.P., Izumchenko E.G. et al. WIF1 is a frequent target for epigenetic silencing in squamous cell carcinoma of the cervix. Carcinogenesis. 2011; 32(11): 1625-33.